The U.S. District Court for the District of Delaware reaffirmed an April 2010 federal jury decision that determined Medtronic's CoreValve willfully infringed Edwards Lifesciences’ Andersen transcatheter heart valve patent and awarded Edwards $74 million in damages.
In its ruling, the court denied Edwards’ request for a permanent injunction to prohibit Medtronic from manufacturing its CoreValve System in the U.S. Therefore, the Minneapolis-based Medtronic does not anticipate any interruption to supply of its CoreValve system, nor does it impact the Medtronic CoreValve U.S. pivotal trial, which began in December.
In the same ruling, the court denied Edwards' motions for increased damages and a permanent injunction relating to Medtronic CoreValve's willful infringement. Edwards plans to appeal these rulings promptly.
Medtronic said it “disagrees” with the court’s conclusion and also announced plans to appeal.